| Autor: |
Blanco-Cantó, Maria Empar, Monge-Argilés, J. A., Gasparini-Berenguer, R., Leiva-Santana, C., Pérez-Cejuela, C., Badía, C., Gabaldón, L., Muñoz-Ruíz, C., Sánchez-Payá, J. |
| Zdroj: |
American Journal of Alzheimer's Disease & Other Dementias; Mar2017, Vol. 32 Issue 2, p101-107, 7p |
| Abstrakt: |
Aim: To compare the diagnostic validity of NIA-AA criteria, for AD CSF biomarkers, with our own new criteria. Materials and Methods: Between 2008 and 2011, 170 patients with Mild Cognitive Impairment (MCI) were included. CSF levels of Aβ1-42, T-tau, P-tau181, and ratios of T-tau/Aβ1-42 and P-tau181/Aβ1-42 were analyzed. In our criteria, we considered 3 or more abnormal variables indicative of a high likelihood of MCI due to AD. Results: After a clinical follow-up of 4.5 ± 1.2 years, 44 patients remained stable, 95 developed AD, 15 other forms of dementia, 7 died and 9 received other diagnoses. Using the NIA-AA criteria and our own criteria, the diagnostic validity of the CSF biomarkers was 58% versus 85%, specificity 84% versus 72%, PPV 82% versus 79% and NPV 61% versus 79%. Conclusion: The inclusion of the ratios in diagnostic criteria increases sensitivity and NPV for the diagnosis of MCI due to AD. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
